Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 365 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metastatic (Stage IV) Melanoma Clear all
Terminated Phase 1 Interventional

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

NCT03865212
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Choroid Melanoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
Interventions
Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 1, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Viral Therapy in Treating Patients With Metastatic Melanoma

NCT00651157
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
wild-type reovirus
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Oct 1, 2026, 9:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

NCT03325101
View directory record Official record
Conditions
Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Cryosurgery, Pembrolizumab, Pheresis, Therapeutic Autologous Dendritic Cells
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 1, 2026, 9:23 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma

NCT02831933
View directory record Official record
Conditions
Lung Squamous Cell Carcinoma Stage IV, Nonsquamous Nonsmall Cell Neoplasm of Lung, Metastatic Uveal Melanoma
Interventions
ADV/HSV-tk, Valacyclovir, SBRT, nivolumab
Biological · Drug · Radiation
Lead sponsor
Eric Bernicker, MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 1, 2026, 9:23 PM EDT
Completed Phase 2 Interventional

Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

NCT00082914
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin)
Interventions
denileukin diftitox
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 1, 2026, 9:23 PM EDT
Not listed Phase 2 Interventional

Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00002845
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin
Biological
Lead sponsor
Blumenthal Cancer Center at Carolinas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 1, 2026, 9:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

NCT06101134
View directory record Official record
Conditions
Melanoma
Interventions
relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab, nivolumab+rHuPH20
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Anchorage, Alaska • Phoenix, Arizona • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 1, 2026, 9:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

NCT04387071
View directory record Official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
Interventions
Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001
Biological · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 1, 2026, 9:23 PM EDT
Not listed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00017355
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
filgrastim, therapeutic autologous dendritic cells
Biological
Lead sponsor
Baylor Health Care System
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 1, 2026, 9:23 PM EDT
Terminated Phase 1 Interventional

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

NCT05341349
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Ocular Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Ipilimumab, Nivolumab, Pembrolizumab, Stereotactic Radiosurgery, Tumor Treating Fields Therapy
Biological · Radiation · Procedure
Lead sponsor
Emory University
Other
Eligibility
22 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 1, 2026, 9:23 PM EDT
Completed Phase 1 Interventional

Decitabine in Treating Patients With Melanoma or Other Advanced Cancer

NCT00002980
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
decitabine
Drug
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 1, 2026, 9:23 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

NCT04356729
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma, Unresectable Stage IV Cutaneous Melanoma
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
F. Stephen Hodi, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 1, 2026, 9:23 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00019448
View directory record Official record
Conditions
Stage IV Melanoma, Recurrent Melanoma
Interventions
gp100 antigen, interleukin-2
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Timeline
1998 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 1, 2026, 9:23 PM EDT
Completed Early Phase 1 Interventional

Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer

NCT00436410
View directory record Official record
Conditions
Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, Kidney Cancer, Liver Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Sarcoma
Interventions
colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study, conventional surgery
Biological · Other · Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Oct 1, 2026, 9:23 PM EDT
Completed Phase 2 Interventional

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

NCT00104988
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
temozolomide, thalidomide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
132
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Castro Valley, California + 89 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced Oct 1, 2026, 9:23 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma

NCT00019175
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, fowlpox virus vaccine vector, gp100 antigen
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 1, 2026, 9:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

NCT02506153
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Metastatic Non-Cutaneous Melanoma, Non-Cutaneous Melanoma, Recurrent Cutaneous Melanoma, Recurrent Mucosal Melanoma, Recurrent Non-Cutaneous Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
552
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 379 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 1, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

NCT00669019
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IV Melanoma
Interventions
saracatinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 1, 2026, 9:23 PM EDT
Completed Phase 2 Interventional

A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma

NCT01009775
View directory record Official record
Conditions
Melanoma
Interventions
YM155, Docetaxel
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Mobile, Alabama • Tuscon, Arizona • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2015 · Synced Oct 1, 2026, 9:23 PM EDT
Completed Phase 3 Interventional Results available

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

NCT00094653
View directory record Official record
Conditions
Melanoma, Metastases
Interventions
MDX-010 (anti-CTLA4) monoclonal antibody, MDX-1379 (gp100) Melanoma Peptide Vaccine
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
110
States / cities
Tucson, Arizona • Duarte, California • Encinitas, California + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Oct 1, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

NCT00521001
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
everolimus, temozolomide
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
198
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 124 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 1, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

NCT03765229
View directory record Official record
Conditions
Melanoma
Interventions
Entinostat, Pembrolizumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 1, 2026, 9:23 PM EDT
Completed Phase 1 Interventional

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma

NCT00004244
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin)
Interventions
recombinant interferon alfa, recombinant interleukin-12
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 1, 2026, 9:23 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma

NCT00004148
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
recombinant vaccinia-B7.1 vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 1, 2026, 9:23 PM EDT